Time for action on viral hepatitis

Annals of the Academy of Medicine Singapore

Volumn 45, Issue 1, 2016, Pages 27-30

  Lim, Seng Gee ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Eradication; Hepatitis C; Linkage to care; Outbreaks; Screening; Treatment

Indexed keywords

ENTECAVIR; SOFOSBUVIR PLUS VELPATASVIR; TENOFOVIR; ANTIVIRUS AGENT; HEPATITIS B VACCINE;

ARTICLE; DRUG INTERACTION; GENOTYPE; HEMODIALYSIS; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER CIRRHOSIS; PUBLIC HEALTH SERVICE; SEROPREVALENCE; VIRUS HEPATITIS; DISEASE OUTBREAKS; HEALTH CARE DELIVERY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; PATIENT SELECTION; RISK ASSESSMENT; SINGAPORE;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; SINGAPORE;

EID: 85012838764     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lim SG. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings. World J Gastroenterol 2015;21:1972-81.
2. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
4. Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015;30:423-33.
5. Ward JW, Mermin JH. Simple, effective, but out of reach? public health implications of hcv drugs. N Engl J Med 2015;373:2678-80.
6. Honer Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 2015:Epub ahead of print.
7. Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks reported to the centers for disease control and prevention (CDC) 2008-2014. Available at: http://www.cdc.gov/hepatitis/outbreaks/pdfs/healthcareinvestigationtable.pdf. Accessed on 27 December 2015.
8. Ministry of Health, Singapore. Hepatitis C cluster in the renal ward of Singapore General Hospital Ministry of Health. Available at: https://www.moh.gov.sg/content/dam/moh_web/PressRoom/Current_Issues/2015/IRCReport.pdf. Accessed on 27 December 2015.
9. Tambyah P. Unusual factors in SGH hepatitis C outbreak. The Straits Times. 12 December 2015. Available at: http://www.straitstimes.com/opinion/unusual-factors-in-sgh-hepatitis-c-outbreak. Accessed on 27 December 2015.
10. Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, et al. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol 2012;54:106-9.
11. Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis 2014;209:1205-11.
12. McAllister G, Shepherd S, Templeton K, Aitken C, Gunson R. Long term stability of HBsAg, anti-HBc and anti-HCV in dried blood spot samples and eluates. J Clin Virol 2015;71:10-7.
13. Tjotta E, Hungnes O, Grinde B. Survival of HIV-1 activity after disinfection, temperature and pH changes, or drying. J Med Virol 1991;35:223-7.
14. Gautret P, Gray GC, Charrel RN, Odezulu NG, Al-Tawfiq JA, Zumla A, et al. Emerging viral respiratory tract infections--environmental risk factors and transmission. Lancet Infect Dis 2014;14:1113-22.
15. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int 2013;33 Suppl 1:68-79.
16. Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis 2014;46 Suppl 5:S158-64.
17. Bennett H, McEwan P, Sugrue D, Kalsekar A, Yuan Y. Assessing the long-term impact of treating hepatitis c virus (hcv)-infected people who inject drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One 2015;10:e0125846.
18. Cairns G. HIV treatment as prevention. Available at: http://www.aidsmap. com/page/1270646/. Accessed on 27 December 2015.
19. Chow WC, Tien SL, Tan CK, Lui HF, Vathsala A, Ng HS. Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia--the Singapore experience. Intervirology 2006;49:107-11.
20. Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, et al. Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015. MMWR Morb Mortal Wkly Rep 2015;64:753-7.
21. Yap I, Guan R, Kang JY, Tay HH, Lee E, Choong L, et al. Seroprevalence of antibodies to the hepatitis C virus in Singapore. Southeast Asian J Trop Med Public Health 1991;22:581-5.
22. Kuperan P, Choon AT, Ding SH, Lee G. Prevalence of antibodies to hepatitis C virus in relation to surrogate markers in a blood donor population of Singapore. Southeast Asian J Trop Med Public Health 1993;24 Suppl 1:127-9.
23. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32.
24. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58-68.
25. Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 1999;5:294-300.
26. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015;13:1993-2001.
27. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;46:923-7.
28. Saxena V, Terrault NA. Treatment of hepatitis C infection in renal transplant recipients: the long wait is over. Am J Transplant 2015. [Epub ahead of print].
29. The Straits Times. Swat team' may be set up to tackle disease outbreaks. 29 December 2015. Available at: http://www.straitstimes.com/singapore/health/swat-team-may-be-set-up-to-tackle-disease-outbreaks. Accessed on 29 December 2015.
30. Guan R. Hepatitis B virus infection in Singapore. Gut 1996;38 Suppl 2:S13-7.
31. Ang LW, Cutter J, James L, Goh KT. Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine 2013;32:103-10.
32. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2015. [Epub ahead of print].
33. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
34. Wai CT, Mak B, Chua W, Lim SG. The majority of hepatitis B carriers are not on regular surveillance in Singapore. Singapore Med J 2004;45:423-6.
35. Wai CT, Mak B, Chua W, Tan MH, Ng S, Cheok A, et al. Misperceptions among patients with chronic hepatitis B in Singapore. World J Gastroenterol. 2005;11:5002-5.
36. Wai CT, Wong ML, Ng S, Cheok A, Tan MH, Chua W, et al. Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B. Aliment Pharmacol Ther 2005;21:1255-62.
37. Lim SG, Aung MO, Chung SW, Soon CS, Mak BH, Lee KH. Patient preferences for hepatitis B therapy. Antivir Ther 2013;18:663-70.
38. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, et al. Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26.
39. Phyo WW, Soh AY, Lim SG, Lee GH. Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol. 2015;7:1272-81.
40. World Health Assembly. Viral hepatitis. Available at: http://apps.who. int/gb/ebwha/pdf_files/WHA63/A63_R18-en.pdf. Accessed on 27 December 2015.